Related Experiment Video
Updated: Jun 2, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Elevated soluble CD40 ligand in diabetic patients with painless myocardial infarction
Yu Huang1, Jianping Qiu, Denghai Zhang
1Department of Cardiology, Gongli Hospital of Shanghai Pudong New District, Shanghai, China.
Insights
Soluble CD40 ligand (sCD40L) may serve as a key biomarker for painless myocardial infarction (MI) in diabetic individuals. This finding could improve diagnosis and treatment for painless MI in this patient population.
Area of Science:
- Cardiology
- Immunology
- Biomarker Discovery
Background:
- Painless myocardial infarction (MI) poses diagnostic challenges in diabetic patients.
- A specific, reliable biomarker for painless MI in diabetes is currently lacking.
Purpose of the Study:
- To identify a potential biomarker for painless MI in patients with diabetes mellitus.
- To compare inflammatory cytokine profiles between painless MI, painful MI, stable coronary heart disease (CHD), and control groups.
Main Methods:
- Case-control study involving 111 diabetic patients and 30 controls.
- Analysis of plasma levels of high sensitivity C-reactive protein (HsCRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and soluble CD40 ligand (sCD40L) using ELISA.
- Comparison of baseline characteristics and cytokine levels across study groups.
Main Results:
- Patients with MI showed elevated levels of sCD40L, HsCRP, IL-6, and TNF-α compared to controls.
- Patients with painless MI exhibited significantly higher sCD40L and IL-6 levels than those with painful MI.
- No significant differences in baseline characteristics were found among patient groups.
Conclusions:
- Soluble CD40 ligand (sCD40L) shows promise as a biomarker for painless MI in diabetic patients.
- Elevated sCD40L and IL-6 levels are associated with painless MI in this population.
- Further research is needed to validate sCD40L's diagnostic utility and understand its elevation mechanisms.
Abstract:
Because a useful biomarker for painless myocardial infarction (MI) has yet to be identified, the aim of this study was to identify a biomarker for diabetic patients with painless MI. A case-control design was used to compare inflammatory cytokine levels among 111 patients with diabetes mellitus, including 31 patients with stable coronary heart disease (CHD), 30 patients with painful MI, 20 patients with painless MI, and 30 age- and sex-matched patients without CHD (control group). In addition to baseline parameters, cytokine levels, including plasma high sensitivity C-reactive protein (HsCRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and soluble CD40 ligand (sCD40L) levels, were analyzed using enzyme-linked immunosorbent assays (ELISAs). No differences in baseline characteristics were observed for patients with painless MI as compared to the other patient groups. Significantly higher sCD40L, HsCRP, IL-6, and TNF-α levels were detected in patients with MI, and markedly elevated sCD40L and IL-6 levels were observed in patients with painless MI as compared to those with painful MI. sCD40L may be a useful biomarker for painless MI in diabetic patients, which could reduce misdiagnosis and expedite treatment. Further studies are required to validate the diagnostic utility of this putative biomarker as well as investigate the mechanism by which sCD40L is elevated in these patients.
